FDA is outlining a streamlined clinical development path for COVID-19 vaccines against emerging variants based on clinical immunogenicity studies, and it’s time for manufacturers to start those trials,...

Eutilex hopes data from an upcoming Phase I trial of its anti-4-1BB antibody will help land the South Korean biotech a global licensing partner for the compound, VP and Head of Open Innovation and Global Strategy...

AC Immune believes it has hit on a breakthrough in vaccine technology with its Alzheimer’s candidate ACI-35. The rest of the world will have to wait to evaluate the claim, as the company and partner...

BigHat, which raised $19 million in an A round led by Andreessen Horowitz on Wednesday, is marrying lab assays with machine learning to optimize antibodies for properties beyond target engagement.  The San Carlos, Calif.-based company’s three...

A new partnership with Pfizer for its RA program gets Imcyse another step closer to raising its next round of financing that would support clinical trials of its pipeline through at least 2023. On Wednesday...

Data on the vulnerability of mAbs to emerging SARS-CoV-2 variants supports the hypothesis that antibodies that bind epitopes conserved across coronavirus species will be most resilient to mutations. Recent...

Moderna is taking a two-pronged approach to addressing potentially weakened vaccine protection against SARS-CoV-2 variants by evaluating an additional booster shot of its current vaccine — a solution...

Having helped create the fastest vaccine development programs in history, Moncef Slaoui has stepped down as scientific adviser and co-leader of Operation Warp Speed, the U.S. government’s initiative to develop, manufacture and distribute countermeasures to COVID-19. Slaoui and...